VBI Vaccines completes Epixis acquisition to focus on CMV vaccine candidate
This article was originally published in Scrip
Executive Summary
US biotechnology company, VBI Vaccines has completed the acquisition of the French biotech, Epixis, a company developing its "eVLP" platform technology for a new generation of Virus-Like Particle (VLP) vaccines. The terms of the acquisition were not disclosed.